A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Project: Other project

StatusFinished
Effective start/end date9/1/136/30/18

Funding

  • Novartis Pharmaceuticals Corporation: $152,162.92